ROSTAB

Rosuvastatin

CARDIOVASCULAR

INDICATION

Heterozygous Hypercholesterolemia (Familial and Nonfamilial) Homozygous Hypercholesterolemia (Familial) Mixed Dyslipidemia.

DOSAGE AND ADMINISTRATION

Heterozygous Hypercholesterolemia (Familial and Nonfamilial) and Mixed Dyslipidemia.  The usual recommended starting dose of Rosuvastatin is 10 mg once daily. Initiation of therapy with 5 mg once daily may be considered for patients requiring less aggressive LDL–C reductions or who have predisposing factor for myopathy. For patients with marked hypercholesterolemia (LDL-C > 190 mg /dl) and aggressive lipid target a 20 mg starting dose may be considered. The 40 mg dose of Rosuvastatin should be reserved for those patients who have not achieved goal LDL-C at 20 mg. After initiation and /or upon titration of Rosuvastatin, lipid level should be analyzed within 2 to 4 weeks and dosage adjusted accordingly. Homozygous Hypercholesterolemia (Familial) :The recommended starting dose of Rosuvastatin is 20 mg once daily in patients with homozygous FH. The maximum recommended dose of Rosuvastatin is 40 mg. Rosuvastatin should be used in these patients as an adjunct to other lipid lowering treatments (eg. LDL apheresis) or if such treatments are unavailable.

COMPOSITION

Rostab 5 : Rosuvastatin Calcium INN equivalent to Rosuvastatin 5 mg.  Rostab 10 : Rosuvastatin Calcium INN equivalent to Rosuvastatin 10 mg. Rostab 20 : Rosuvastatin Calcium INN equivalent to Rosuvastatin 20 mg.